# A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Source: https://onco.cc/trials/nct05867420/  
OnCo record `nct05867420` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Bevacizumab, Fruquintinib and Docetaxel in advanced solid tumours, run by AskGene Pharma, Inc., now recruiting.

## Summary

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT05867420 by AskGene Pharma, Inc., with 594 participants planned, started 2023-08-02 and due to reach its primary completion in 2026-12-31. Interventions recorded: ASKG915, Paclitaxel + Bevacizumab, Fruquintinib and Docetaxel.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05867420
- Phase: 1/2
- Setting: A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASKG915 in Patients With Selected Advanced Solid Tumors
- Sponsor: AskGene Pharma, Inc.
- Enrolled: 594

## Sources

- ClinicalTrials.gov NCT05867420: https://clinicaltrials.gov/study/NCT05867420

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Fruquintinib](https://onco.cc/drugs/fruquintinib/)
- companies: [AskGene Pharma](https://onco.cc/companies/askgene-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05867420.json